Selda Samakoglu

867 total citations
20 papers, 635 citations indexed

About

Selda Samakoglu is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Selda Samakoglu has authored 20 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Genetics and 7 papers in Oncology. Recurrent topics in Selda Samakoglu's work include Virus-based gene therapy research (6 papers), Hemoglobinopathies and Related Disorders (5 papers) and CRISPR and Genetic Engineering (4 papers). Selda Samakoglu is often cited by papers focused on Virus-based gene therapy research (6 papers), Hemoglobinopathies and Related Disorders (5 papers) and CRISPR and Genetic Engineering (4 papers). Selda Samakoglu collaborates with scholars based in United States, United Kingdom and Italy. Selda Samakoglu's co-authors include Isabelle Rivière, Stephen M. Ansell, Michel Sadelain, John M. Timmerman, Anne Sumbul, Leszek Lisowski, Philippe Armand, Scott J. Rodig, Peter Johnson and Nishitha Reddy and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Selda Samakoglu

19 papers receiving 628 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Selda Samakoglu United States	12	353	258	188	165	165	20	635
Keshu Zhou China	14	306 0.9×	338 1.3×	220 1.2×	307 1.9×	153 0.9×	111	785
Jettie J.F. Muris Netherlands	13	290 0.8×	197 0.8×	277 1.5×	75 0.5×	260 1.6×	16	656
Nancy Pennell Canada	13	234 0.7×	260 1.0×	191 1.0×	132 0.8×	143 0.9×	31	547
Candida Vitale Italy	16	358 1.0×	244 0.9×	160 0.9×	413 2.5×	395 2.4×	46	832
Tomohiro Aoki Japan	16	304 0.9×	257 1.0×	177 0.9×	102 0.6×	184 1.1×	45	686
J. Graham Sharp United States	12	250 0.7×	159 0.6×	181 1.0×	96 0.6×	113 0.7×	26	633
Vasantha Brito‐Babapulle United Kingdom	15	233 0.7×	457 1.8×	171 0.9×	498 3.0×	283 1.7×	29	773
Marion Alcantara France	9	259 0.7×	145 0.6×	103 0.5×	74 0.4×	121 0.7×	24	402
G Wong United States	8	163 0.5×	182 0.7×	106 0.6×	121 0.7×	97 0.6×	10	391
Weihong Chen China	5	186 0.5×	209 0.8×	117 0.6×	136 0.8×	152 0.9×	8	396

Countries citing papers authored by Selda Samakoglu

Since Specialization

Citations

This map shows the geographic impact of Selda Samakoglu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Selda Samakoglu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Selda Samakoglu more than expected).

Fields of papers citing papers by Selda Samakoglu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Selda Samakoglu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Selda Samakoglu. The network helps show where Selda Samakoglu may publish in the future.

Co-authorship network of co-authors of Selda Samakoglu

This figure shows the co-authorship network connecting the top 25 collaborators of Selda Samakoglu. A scholar is included among the top collaborators of Selda Samakoglu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Selda Samakoglu. Selda Samakoglu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Wang, Marilene B., Saroj K. Basak, Eri S. Srivatsan, et al.. (2025). Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, single arm trial.. Journal of Clinical Oncology. 43(16_suppl). 6087–6087.

2.

Chesney, Jason, Adam J. Schoenfeld, Trisha M. Wise‐Draper, et al.. (2022). Abstract CT130: Trial in progress: A phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating lymphocyte (TIL) cell therapy (LN-145) in patients with metastatic non-small cell lung cancer (mNSCLC). Cancer Research. 82(12_Supplement). CT130–CT130. 2 indexed citations

3.

Aroldi, Francesca, Mark R. Middleton, Joseph J. Sacco, et al.. (2021). 1093TiP An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]. Annals of Oncology. 32. S903–S904. 2 indexed citations

4.

Aroldi, Francesca, Joseph J. Sacco, Kevin J. Harrington, et al.. (2020). 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors. SHILAP Revista de lepidopterología. A256.2–A257. 6 indexed citations

5.

Armand, Philippe, Ann Janssens, Giuseppe Gritti, et al.. (2020). Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 137(5). 637–645. 70 indexed citations

6.

Hong, David S., Drew Rasco, Michael H. Veeder, et al.. (2019). A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology. 97(2). 102–111. 66 indexed citations

7.

Ansell, Stephen M., Monique C. Minnema, Peter Johnson, et al.. (2019). Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 37(6). 481–489. 249 indexed citations

8.

Hong, David S., Drew Rasco, Michael H. Veeder, et al.. (2018). A multicenter study of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2578–2578. 2 indexed citations

9.

Samakoglu, Selda, Dhanvanthri S. Deevi, Huiling Li, et al.. (2012). Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.. PubMed. 9(2). 77–92. 20 indexed citations

10.

Prewett, Marie, Rajiv Bassi, Keren Paz, et al.. (2011). Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.. PubMed. 31(6). 2149–60. 2 indexed citations

11.

Duignan, Inga, Erik Corcoran, Mary Jane Plym, et al.. (2011). Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models. Neoplasia. 13(1). 49–59. 14 indexed citations

12.

Deevi, Dhanvanthri S., Selda Samakoglu, Nieves Martell Claros, et al.. (2010). 85 Mechanisms underlying the therapeutic benefit of necitumumab (IMC-11F8) in combination with cisplatin/gemcitabine in NSCLC xenograft models. European Journal of Cancer Supplements. 8(7). 35–35. 1 indexed citations

13.

Olszewska, Malgorzata, et al.. (2008). Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring γ-retrovirus-encoded hsvtk suicide genes. Gene Therapy. 15(21). 1454–1459. 3 indexed citations

14.

Sadelain, Michel, Leszek Lisowski, Selda Samakoglu, et al.. (2005). Progress Toward the Genetic Treatment of the β‐Thalassemias. Annals of the New York Academy of Sciences. 1054(1). 78–91. 27 indexed citations

15.

Samakoglu, Selda, Leszek Lisowski, Tülin Budak-Alpdoǧan, et al.. (2005). A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nature Biotechnology. 24(1). 89–94. 91 indexed citations

16.

Sadelain, Michel, Stefano Rivella, Leszek Lisowski, Selda Samakoglu, & Isabelle Rivière. (2004). Globin gene transfer for treatment of the β-thalassemias and sickle cell disease. Best Practice & Research Clinical Haematology. 17(3). 517–534. 15 indexed citations

17.

Sadelain, Michel, Stefano Rivella, Leszek Lisowski, Selda Samakoglu, & Isabelle Rivière. (2004). Globin gene transfer for treatment of the β-thalassemias and sickle cell disease. Best Practice & Research Clinical Haematology. 17(3). 517–534. 12 indexed citations

18.

Samakoglu, Selda, Delphine Bohl, & Jean Michel Heard. (2002). Mechanisms Leading to Sustained Reversion of β-Thalassemia in Mice by Doxycycline-Controlled Epo Delivery from Muscles. Molecular Therapy. 6(6). 793–803. 16 indexed citations

19.

Samakoglu, Selda, Elena Fattori, Stefania Lamartina, et al.. (2001). βMinor-globin messenger RNA accumulation in reticulocytes governs improved erythropoiesis in β thalassemic mice after erythropoietin complementary DNA electrotransfer in muscles. Blood. 97(8). 2213–2220. 21 indexed citations

20.

Samakoglu, Selda, Sjaak Philipsen, Frank Grosveld, Güven Lüleci, & Hüseyin Bağcı. (1999). Nucleotide changes in the γ-globin promoter and the (AT)xNy(AT)z polymorphic sequence of βLCRHS-2 region associated with altered levels of HbF. European Journal of Human Genetics. 7(3). 345–356. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact